John D. Shaughnessy

High Impact

Professor

UAMS primary UA Little Rock

Also affiliated: University of Maryland, Baltimore (2003); National Institutes of Health (1993); Arkansas Children's Hospital (1998); Langley Research Center (1973–1992); Hackensack University Medical Center (2003); Memorial Sloan Kettering Cancer Center (2003); Harvard University (2013); Central South University (2023); Inserm (2002–2003); Duke University (2009); University of Basel (2005); BP (United Kingdom) (2001–2007); Medical College of Wisconsin (2003); Cornell University (2001); University of Utah (2009); University of Arkansas Medical Center (2014); Harvard University Press (2008); Aarhus University Hospital (2002); Saint Vincent Health System (2003); Yale University (2009); Institut National de Recherche en Santé Publique (2003); Fred Hutch Cancer Center (2000); Centre Hospitalier Universitaire de Montpellier (2002); Genesis Laboratories (1995); Cancer Research And Biostatistics (2003–2012); Dana-Farber Cancer Institute (2013); Signal Genetics (United States) (2012–2016); Mayo Clinic in Arizona (2009); University of Applied Management Studies (2024); Duke Medical Center (2009); Cancer Research Center (1995–2007); Winthrop Rockefeller Foundation (2008–2025); Frederick National Laboratory for Cancer Research (1996); Hôpital Lapeyronie (2002); University of Wisconsin Health (2012); The Institute of Statistical Mathematics (2012); National Cancer Institute (1990–2012); Hôpital Saint Eloi (2003); Arkansas Children's Nutrition Center (2025); Center for Cancer Research (1995–1997); The US Oncology Network (2009); Institute for Myeloma & Bone Cancer Research (2002–2009); PDL BioPharma (United States) (2006); International Myeloma Foundation (2004); Department of Health and Human Services (1993); SWOG Cancer Research Network (2000); Best Biotech (2009); Bristol-Myers Squibb (Switzerland) (2001); University of Maryland, College Park (1990); Icahn School of Medicine at Mount Sinai (2016–2018)

Faculty Researcher

Internal Med, College of Medicine

88 h-index 482 pubs 31,352 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

John D. Shaughnessy is a Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences. His research focuses on multiple myeloma, including its genetic underpinnings, the tumor microenvironment, and treatment strategies. He has investigated the genetic alterations associated with the complexity and progression of multiple myeloma, as well as the role of specific genes like TRIP13 in the development of B cell malignancies.

Dr. Shaughnessy's work also examines emerging therapeutic approaches for multiple myeloma, such as bispecific antibodies and chimeric antigen receptor (CAR)-T cells. His publications include analyses of infection risks associated with bispecific antibody use and studies on the efficacy of bispecific CAR-T cells targeting BCMA/CD24. Furthermore, his research addresses disparities in access to advanced multiple myeloma treatments, including CAR-T cell and bispecific antibody trials, examining geographic and racial factors.

He collaborates extensively with colleagues at the University of Arkansas for Medical Sciences, including Fenghuang Zhan, Clyde Bailey, Guido Tricot, and Maurizio Zangari. Dr. Shaughnessy is a highly cited researcher with an h-index of 88 and over 482 publications.

Metrics

h-index: 88
Publications: 482
Citations: 31,352

Selected Publications

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

DOI OpenAlex
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

DOI OpenAlex
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study (2025)

DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

3 citations DOI OpenAlex
Abstract 860: BCMA CAR-T cells releasing mutant CST6 N137D proteins further improve therapeutic effects in multiple myeloma (2025)

DOI OpenAlex
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience (2025)

DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

1 citation DOI OpenAlex
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)

4 citations DOI OpenAlex
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)

5 citations DOI OpenAlex
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)

4 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

Developmental Funds Pilot of the Southwest Oncology Group-SWOG-01047 NIH/Nat. Cancer Institute Principal Investigator
Gene expression profiling vs MRD assessment in Myeloma NIH Co-Investigator
Studying the role of APRIL and BAFF signaling in Myelomagenesis and its Therapy ZymoGenetics, Inc Principal Investigator
Preclinical Studies of the Mechanisms of Action of Velcade Millennium Pharmaceuticals, Inc. Principal Investigator
Molecular Diagnosis and Prognosis of Multiple Myeloma NIH/Nat. Cancer Institute Principal Investigator
U54 - Bioinformatics Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator
Myeloma-Microenvironment Interaction Dynamics NIH Co-Investigator
U54 - Administrative Core NIH/Nat. Cancer Institute via Baylor College of Medicine Principal Investigator